2022
EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression
Mutlu L, Manavella D, Bellone S, Santin A. EP015/#546 In vitro and in vivo efficacy of trastuzumab deruxtecan (T-DXd) in epithelial ovarian cancer with HER2/NEU overexpression. 2022, a54.2-a54. DOI: 10.1136/ijgc-2022-igcs.106.Peer-Reviewed Original ResearchHER2/neu overexpressionEpithelial ovarian cancerTrastuzumab deruxtecanNeu overexpressionOvarian cancerVivo efficacy
2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBenzodiazepinesBystander EffectCell Line, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMiddle AgedPrimary Cell CultureReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neuPrimary USC cell linesUSC cell linesUterine serous carcinomaSerous carcinomaHER2/Cell linesBystander killingHER2/neu protein expressionHER2/neu overexpressionProtein expressionNovel treatment optionsAggressive histologic variantNeu protein expressionHER2 protein expressionC-erbB2 gene amplificationSignificant bystander killingUSC xenograftsEndometrial cancerNegative tumorsPoor prognosisPositive tumorsTreatment optionsPreclinical activityHistologic variants
2020
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
Pelligra S, Buza N, Hui P, Bellone S, Zeybek B, Ratner E, Schwartz PE, Scambia G, Santin AD. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020, 32: 100554. PMID: 32140533, PMCID: PMC7049633, DOI: 10.1016/j.gore.2020.100554.Peer-Reviewed Original ResearchUterine serous carcinomaHER2/neuNegative tumor cellsUSC patientsTumor cellsSerous carcinomaHER2/neu overexpressionCarboplatin/paclitaxelInitial clinical responsePost-treatment biopsiesHumanized monoclonal antibodyC-erbB2 gene amplificationNCCN guidelinesClinical responseEndometrial cancerPreferred regimenAggressive variantMechanisms of resistanceNeu overexpressionRecurrent/HER2/TrastuzumabPatientsMonoclonal antibodiesNeu
2005
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal Of Obstetrics And Gynecology 2005, 192: 813-818. PMID: 15746676, DOI: 10.1016/j.ajog.2004.10.605.Peer-Reviewed Original ResearchConceptsHER2/neu expressionEndometrial cancerNeu expressionProportional hazards modelWhite patientsBlack patientsPoor outcomeHigh HER2/neu expressionUterine serous papillary cancerCox proportional hazards modelHER2/neu overexpressionEndometrial cancer survivalMultivariate Cox regressionMajor prognostic indicatorHER2/neu oncogeneRacial differencesNovel treatment strategiesHER2/neuType II receptorStage IAAggressive variantMultivariable analysisUnivariable analysisCorpus uteriCox regression3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer
Santin A. 3 Role of Immunohistochemical Expression of HER2/neu in High-Grade Ovarian Serous Papillary Cancer. Handbook Of Immunohistochemistry And In Situ Hybridization Of Human Carcinomas 2005, 4: 333-338. DOI: 10.1016/s1874-5784(05)80089-3.Peer-Reviewed Original ResearchHER2/neuEpidermal growth factor receptorHER2/neu protein overexpressionLymphocyte-activated killer cellsTumor necrosis factor alphaHER2/neu overexpressionPapillary cancer tissuesVascular endothelial growth factorNecrosis factor alphaShorter patient survivalHER2/neu functionNeu protein overexpressionEndothelial growth factorHER2/neu gene productGrowth factor receptorHormonal therapyKiller cellsGynecologic tumorsPatient survivalPapillary cancerNeu overexpressionOvarian carcinomaHistologic evaluationImmunohistochemical expressionDifferential diagnosis